Search
Triheptanoin
go.drugbank.com/drugs/DB11677ApprovedInvestigational[A214817] Triheptanoin was granted FDA approval on 30 June 2020.[L14612]
Voriconazole
go.drugbank.com/drugs/DB00582ApprovedInvestigational[A236050] Voriconazole was approved by the FDA under the trade name Vfend on May 24, 2002.[L34660]
Products: INVOTAS® 50 MG TABLETAS CUBIERTAS CON PELÍCULA, INVOTAS® 200 MG TABLETAS RECUBIERTAS CON PELÍCULATrilaciclib
go.drugbank.com/drugs/DB15442ApprovedInvestigational[A229313] Trilaciclib was granted FDA approval on 12 February 2021.[L31823]
Mito-4509
go.drugbank.com/drugs/DB05846ExperimentalMito-4509 is a non-feminizing estrogen analog that could affect mitochondrial metabolic pathways.
Apricoxib
go.drugbank.com/drugs/DB12378InvestigationalApricoxib has been used in trials studying the treatment and prevention of Lung Cancer, Breast Cancer, Pancreatic Cancer, Non Small Cell Lung Cancer, and Metastatic Pancreatic Cancer, among others.
Sonolisib
go.drugbank.com/drugs/DB12601InvestigationalSonolisib has been used in trials studying the treatment of Glioblastoma, Prostate Cancer, Advanced Solid Tumors, Advanced BRAF-mutant Cancers, and Non Small Cell Lung Cancer (NSCLC), among others.
AP103
go.drugbank.com/drugs/DB18234ExperimentalAP103 is a non-viral gene therapy that uses a delivery vector, HPAE (Highly Branched Poly β-Amino Ester), to deliver the correct collagen VII gene into skin cells.
Cycloleucine
go.drugbank.com/drugs/DB04620ExperimentalCycloleucine is non-metabolisable amino acid formed by cyclization of leucine. It is also a specific and reversible inhibitor of nucleic acid methylation and widely used in biochemical experiments.
Firmonertinib
go.drugbank.com/drugs/DB16087InvestigationalAlflutinib is under investigation in clinical trial NCT03452592 (Efficacy and Safety of Alflutinib in Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients With T790M).
Pamapimod
go.drugbank.com/drugs/DB19169InvestigationalPamapimod is under investigation in clinical trial NCT05659459 (The KIN-FAST Trial (KIN001 for Accelerated Symptoms Termination) in Non Hospitalized Patients Infected With Sars-cov-2).